Meibomian gland dysfunction assessments in children a highlight at the Tear Film & Ocular Surface Society's 2024 meeting.

For treatment, injections deliver a monoclonal antibody to stop the growth of the blood vessels. The hope is that this allows ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has dosed its first patient in a clinical trial for its innovative ...

Biotech player PYC Therapeutics (ASX:PYC) has dosed its first patient in a clinical trial seeking to ameliorate symptoms of ...

As October draws to a close, it's time to take a look at the regulatory news that made headlines in the month and look ahead to ...

S cience Corporation, a rival to Elon Musk’s Neuralink in the development of brain-computer interface (BCI) technology, has just unveiled promising early clinical trial results for an eye implant that ...

Shares of Apellis Pharmaceuticals (NASDAQ: APLS) are down by about 62% from the peak they reached in January. However, ...

It is caused by abnormal blood vessel growth (a condition referred to as 'wet' macular degeneration) or atrophy and accumulation of debris ('dry' macular degeneration), both of which damage the ...

“These are devastating diseases with limited treatment options,” said Curt Breneman, Ph.D., dean of Rensselaer’s School of ...

Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder ...